AR053891A1 - Derivados de indol que tienen actividad antitumoral - Google Patents

Derivados de indol que tienen actividad antitumoral

Info

Publication number
AR053891A1
AR053891A1 ARP060102385A ARP060102385A AR053891A1 AR 053891 A1 AR053891 A1 AR 053891A1 AR P060102385 A ARP060102385 A AR P060102385A AR P060102385 A ARP060102385 A AR P060102385A AR 053891 A1 AR053891 A1 AR 053891A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
same
alkanoyl
branched
Prior art date
Application number
ARP060102385A
Other languages
English (en)
Inventor
Claudio Pisano
Gianfranco Battistuzzi
Marzo Maria Di
Giuseppe Giannini
Mauro Marzi
Loredana Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR053891A1 publication Critical patent/AR053891A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula 1 en donde A = formula 2, A1 es o bien H o A, en donde R, R' y R1 son iguales para los dos anillos indol; X es un alquilo C2-10 lineal o ramificado, ( alquenilo o alquinilo) saturado o insaturado, opcionalmente sustituido con OH, o un arilo C6-10, heteroarilo C3-10 que contiene por lo menos un heteroátomo seleccionado entre N, O o S, en donde en los grupos cíclicos por lo menos uno de los -CH- está opcionalmente sustituido con C-halogeno o C- alquilo-C1-3; -Q=SH, COCONR2R3, COCF3, o : Q = CONGO, COOH, CONH- formula 3 en donde: G es o bien H o un glicosilo; R2, R3 son iguales o diferentes y son o bien H o un alquilo C1.-4; R1 es seleccionado entre el grupo que consiste en H, alquilo C1-4, arilo, arilo-(C6-10)-alquilo (C1-4), alcanoilo C1-4 y alquilo-(1-4)-arilo-(C6-10); R y R' iguales o diferentes, son seleccionados entre el grupo que consiste en: H, alquilo C1-10 lineal o ramificado, saturado o insaturado, opcionalmente sustituido con un heteroarilo C3-10 o heteroátomo seleccionado entre N, O o S o con un grupo -NR5R6, en donde R5, R6 son iguales o diferentes y son H, alquilo C1-5 lineal o ramificado, alcanoilo C1-4, OR4 en donde R4 = H, alquilo C1-4, mesilo, tosilo, alcanoilo C1-4, glicosilo, halogeno, azida, nitro, nitrilo y NR5R6. Se describe también composiciones farmacéuticas que contienen los compuestos arriba mencionados, para el tratamiento de tumores.
ARP060102385A 2005-06-10 2006-06-08 Derivados de indol que tienen actividad antitumoral AR053891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05012562 2005-06-10

Publications (1)

Publication Number Publication Date
AR053891A1 true AR053891A1 (es) 2007-05-23

Family

ID=35062959

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102385A AR053891A1 (es) 2005-06-10 2006-06-08 Derivados de indol que tienen actividad antitumoral

Country Status (13)

Country Link
US (1) US8053460B2 (es)
EP (1) EP1891007A1 (es)
JP (1) JP2008542428A (es)
KR (1) KR20080029967A (es)
CN (1) CN101193861A (es)
AR (1) AR053891A1 (es)
AU (1) AU2006256771A1 (es)
BR (1) BRPI0612542A2 (es)
CA (1) CA2607337A1 (es)
EA (1) EA013542B1 (es)
MX (1) MX2007015274A (es)
TW (1) TW200716545A (es)
WO (1) WO2006131484A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2391605B1 (en) * 2009-01-28 2017-11-08 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
ES2672701T3 (es) * 2012-11-07 2018-06-15 Karus Therapeutics Limited Nuevos inhibidores de histona deacetilasa y su uso en terapia
WO2014181137A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
CN105367479A (zh) * 2015-11-16 2016-03-02 青岛大学 一种组蛋白去乙酰酶抑制剂2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基-n-(2-(羟氨基)-2-酮乙基)乙酰胺及其制备方法和应用
CN109928909A (zh) * 2019-04-02 2019-06-25 南华大学 具有抗抑郁活性化合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887348A1 (en) 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
IT1317925B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Bis-eterocicli ad attivita' antitumorale e chemosensibilizzante.
EP1438044A1 (en) * 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors

Also Published As

Publication number Publication date
BRPI0612542A2 (pt) 2010-11-23
EA200702672A1 (ru) 2008-04-28
EA013542B1 (ru) 2010-06-30
CA2607337A1 (en) 2006-12-14
CN101193861A (zh) 2008-06-04
US20080207729A1 (en) 2008-08-28
EP1891007A1 (en) 2008-02-27
AU2006256771A1 (en) 2006-12-14
KR20080029967A (ko) 2008-04-03
JP2008542428A (ja) 2008-11-27
MX2007015274A (es) 2008-02-22
US8053460B2 (en) 2011-11-08
WO2006131484A1 (en) 2006-12-14
TW200716545A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
AR053891A1 (es) Derivados de indol que tienen actividad antitumoral
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
EA200970535A1 (ru) Антибактериальные производные хинолина
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
MA31419B1 (fr) Derives de pyridine
EA200401194A1 (ru) Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
ATE433447T1 (de) Pyrimiidinverbindungen
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA201100119A1 (ru) Химические соединения 251
EA200700099A1 (ru) Производные пиридина
ATE486872T1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CO5631443A2 (es) Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
ES2243579T3 (es) Derivados de pirazolopirideno.
EA201070018A1 (ru) Замещенные 2-[2-(фенил)этиламино] алканамидные производные и применение указанных соединений в качестве модуляторов натриевых и/или кальциевых каналов
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal